CN106266149A - The application in terms of preparation suppression inflammatory factor medicine of the heat clearing Chinese medicine compositions combined with antibiotic - Google Patents
The application in terms of preparation suppression inflammatory factor medicine of the heat clearing Chinese medicine compositions combined with antibiotic Download PDFInfo
- Publication number
- CN106266149A CN106266149A CN201610663187.2A CN201610663187A CN106266149A CN 106266149 A CN106266149 A CN 106266149A CN 201610663187 A CN201610663187 A CN 201610663187A CN 106266149 A CN106266149 A CN 106266149A
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- application
- radix
- plasma
- medicine composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/19—Acanthaceae (Acanthus family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/29—Berberidaceae (Barberry family), e.g. barberry, cohosh or mayapple
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/738—Rosa (rose)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/758—Zanthoxylum, e.g. pricklyash
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses the application in terms of preparation suppression inflammatory factor medicine of a kind of heat clearing Chinese medicine compositions combined with antibiotic, described inflammatory factor includes plasma endotoxin, Plasma Nitric Oxide and/or plasma TNF；Described antibiotic is azithromycin, and the active component of described Chinese medicine composition is made up of Radix Flemingiae Philippinensis, Herba Andrographis, Radix Rosae Laevigatae, Caulis Mahoniae and Fructus Zanthoxyli Dissiti.The present invention is by azithromycin and the Chinese medicine composition use in conjunction being made up of Radix Flemingiae Philippinensis, Herba Andrographis, Radix Rosae Laevigatae, Caulis Mahoniae and Fructus Zanthoxyli Dissiti five kinds of Chinese medicine, in terms of suppression inflammatory factor, there is good application effect, and by experimental results demonstrate that Chinese medicine composition and azithromycin play synergism, realizing targeted therapy to infect and inflammation, the frontier use in conjunction for Chinese medicine composition and azithromycin provides powerful technique support.
Description
Technical field
The present invention relates to pharmaceutical technology field, more particularly, to a kind of heat clearing Chinese medicine compositions combined with antibiotic in system
Application in terms of standby suppression inflammatory factor medicine.
Technical background
Research finds, infects and time inflammation occurs, and plasma endotoxin, Plasma Nitric Oxide, Levels of tumor are bad in the patient
Necrosis factor produces in a large number, and level is higher than normal value.Tumor necrosis factor (TNF-α) is that activated mononuclear-macrophage produces
Plant important cytokine, at infectious disease and aspect of inflammation, vascular endothelial cell can be stimulated to express adhesion molecule, stimulate list
Core-macrophage and other emiocytosis chemotactic cytokines, cause leukocyte to assemble at inflammation part, promotes that inflammation is anti-
Should, over-reactive excess TNF-α, then produce violent immunoreation, present toxic action, body is caused damage.One oxidation
Nitrogen (nitricoxide, NO), by macrophages secrete, can form Interference fit with superoxide anion reaction
(peroxynitrite, ONOO-), it is decomposed into OH-and NO2 that toxicity is bigger again, and the latter enters target cell or adjacent cells,
Cause cytotoxicity or damage tissue.Endotoxin (LPS): lymphocyte is as the important immunocyte of body, and it is probably
By Toll-like receptor 4 (Toll-likereceptor4, TLR4) and Nuclear factor kappa B (NuclearFactorKappaB, NF-κ B)
Approach, the multiple proinflammatory factor synthesizing and discharging including TNF-α and IL-6, strengthen inflammatory reaction so that proinflammatory/to press down scorching mistake
Weighing apparatus, causes inflammatory reaction extension and immunologic derangement.In above-mentioned reaction path, TLR4 is endotoxin effective ingredient lipopolysaccharide
The ligands specific of (Lipopolysaccharides, LPS), can be combined with LPS, startup inflammatory reaction, and NF-κ B conduct
The Main Factors in TLR4 reaction chain downstream, can combine with the gene promoter sequence of multiple proinflammatory factor, synthesize and discharge phase
The inflammatory factor answered.
Have no that Chinese medicine composition and Antibiotic combination are applied to the correlation technique report of preparation suppression inflammatory factor at present.
Summary of the invention
The technical problem to be solved in the present invention is to fill up the application technology deficiency of existing Chinese medicine composition associating azithromycin,
The application in terms of preparation suppression inflammatory factor medicine of a kind of heat clearing Chinese medicine compositions combined with antibiotic is provided.
The purpose of the present invention is achieved by the following technical programs:
The application in terms of preparation suppression inflammatory factor medicine of the heat clearing Chinese medicine compositions combined with antibiotic, described inflammation are provided
The factor includes plasma endotoxin, Plasma Nitric Oxide and/or plasma TNF；Described antibiotic is azithromycin, institute
The active component stating Chinese medicine composition is made up of Radix Flemingiae Philippinensis, Herba Andrographis, Radix Rosae Laevigatae, Caulis Mahoniae and Fructus Zanthoxyli Dissiti.
Preferably, described heat clearing Chinese medicine compositions associating azithromycin can be advantageously applied to preparation treatment chronic pelvic
Inflammation, inflammation of uterus and/or the medicine aspect of ovary inflammation.
Preferably, in described Chinese medicine composition, the incorporation of Herba Andrographis and Fructus Zanthoxyli Dissiti is respectively the 9% of medical material gross weight；Gold
The incorporation of cherry root, Caulis Mahoniae and Radix Flemingiae Philippinensis is respectively the 16% of medical material gross weight.
Preferably, described application is to be applied to prepare in targeted inhibition blood plasma by heat clearing Chinese medicine compositions associating azithromycin
Toxin, Plasma Nitric Oxide and plasma TNF medicine aspect.
The invention has the beneficial effects as follows:
Azithromycin is applicable to the infection caused by sensitive bacterial, including the lower respiratory infection such as bronchitis, pneumonia, skin
Skin and soft tissue infection, acute otitis media, the upper respiratory tract infection such as sinusitis, pharyngitis, tonsillitis.The present invention is by it and by thousand
Jin pull out, Herba Andrographis, Radix Rosae Laevigatae, Caulis Mahoniae and Fructus Zanthoxyli Dissiti five kinds of Chinese medicine composition Chinese medicine composition use in conjunction, suppression inflammation because of
Sub-aspect has good application effect, and proves that Chinese medicine composition and azithromycin play collaborative work by a large amount of zooperies
Infect and inflammation with, it is achieved targeted therapy, apply for the frontier of Chinese medicine composition and azithromycin and provide powerful technique and prop up
Hold.
Accompanying drawing explanation
Fig. 1 treated with combined medication Plasma Before And After endotoxin situation of change.
Fig. 2 treated with combined medication Plasma Before And After changes of Nitric Oxide situation.
Fig. 3 treated with combined medication Plasma Before And After tumor necrosis factor situation of change.
Fig. 4 detects the NaNO of NO2The dilution step schematic diagram of titer.
Detailed description of the invention
The present invention is further illustrated below in conjunction with specific embodiment.Following embodiment being merely cited for property explanation, it is impossible to reason
Solve as limitation of the present invention.Unless stated otherwise, the raw material used in following embodiment obtains for conventional commercial or commercial sources
The raw material obtained, unless stated otherwise, the method and apparatus used in following embodiment is method commonly used in the art and sets
Standby.
Embodiment 1
1. experimental strain: staphylococcus aureus (ATCC25923), escherichia coli (ATCC25922) is bought in China
Country's strain library.Strain subject lyophilized powder is uniformly laid on aseptic M-H (A) planar surface with after aseptic M-H (B) culture medium suspendible,
35 DEG C of overnight incubation are brought back to life, and 18h rear plate superficial growth goes out lawn, chooses the single cenobium wherein grown fine, again smears
In M-H (A) inclined-plane, under the same terms, hatch 18h, seal, stored refrigerated under the conditions of 4 DEG C；Test takes inclined-plane bacterium and smears the previous day
In M-H (A) flat board, 35 DEG C of overnight incubation, can use.All operations all completes at superclean bench.
2. bacterium solution preparation method
Method one: (prepared by high concentration bacterium solution)
Choose 3～4 single bacterium colonies in M-H (B) culture medium of 40 milliliters.Tested bacterium Zengjing Granule overnight 16 hours (37 DEG C,
Shaking bath shakes 16 hours), take out original bacteria liquid all-wave length multi-functional reading view next day and survey OD value (the bacterial growth period of saturation)；
Take 20mL, be sub-packed in centrifuge tube, often pipe 2mL, centrifugal 10000～15000rpm/min, 10 minutes, abandon or adopt among supernatant
M-H (B), after mixing with 2mL normal saline, then is centrifuged 15000rpm/min, 10 minutes, abandons or adopts the normal saline in supernatant,
Collect bacterial cell thalline 2mL.Gold-coloured staphylococci and the escherichia coli same procedure cultivated i.e. are obtained by 1:1 mixing
4mL mixed bacteria liquid.It is 100 bacterial concentrations by this bacterium solution, carries out 10 times of dilutions with normal saline, be diluted to 0.1 × 100,0.01
× 100, standby (totally 3 dosage).
Method two: (prepared by low concentration bacterium solution)
Choose single bacterium colony (including gold-coloured staphylococci and escherichia coli) in the normal saline of 2 milliliters, to prepare respectively
Become 0.5 Maxwell concentration (about 1 × 108CFU mL-1) bacterial suspension, by gold-coloured staphylococci and escherichia coli suspension
Mixing, i.e. obtains mixed bacteria liquid 4mL.This bacterium solution is set to 10A bacterial concentration, carries out two-fold dilution with normal saline, dilute
Release to 0.5 × 10A, 0.25 × 10A, standby (totally 3 dosage).
3. medicine and reagent: M-H (A) culture medium (OXOID company, product batch number: CM0337A)；M-H (B) culture medium
(OXOID company, product batch number: CM0405B)；Urethane solution (20%)；Normal saline (Cologne, the Sichuan limited public affairs of medicinal liquid share
Department, product batch number: M12012004)；Other reagent and consumptive material are bought by Chengdu Ya Rong biochemical equipment business department and are provided.
4. instrument: electro-heating standing-temperature cultivator (the permanent Science and Technology Ltd. in Shanghai one, BPH-9162)；Excellent general series ultrapure water machine
(Chengdu Ultra Pure Science & Technology Co., Ltd, UpK-1-10T)；Micro sample adding appliance (EppendorfResearch, 10,100,100uL)；
Air bath agitator (the connection electronic technology exploitation of east, Harbin City, HZQ-C)；Automatic electric heating pressure steam sterilization boiler (pacify by Shen, Shanghai
Medical apparatus and instruments factory, LDZX-40BI)；All-wave length multi-functional reading view (U.S. Thermo)；Bacterial colony counting instrument.
5.IL-1 β (interleukin-11 β), LPS (endotoxin), TNF-α (tumor necrosis factor), NO (nitric oxide) detection side
Method
Reference reagent box operation instructions, carry out coherent detection.
(1)IL-1β
1, sample-adding: set gauge orifice, testing sample hole, blank well respectively.If gauge orifice 7 hole, it is sequentially added into 100 μ L differences dense
The standard substance (preparing 2 see reagent) of degree.Blank well adds 100 μ L (preparing last pipe of second step see reagent), and remaining hole adds treats test sample
Product 100 μ L, ELISA Plate adds overlay film, 37 DEG C of incubations 2 hours.
2, discard liquid, dry, need not wash.
3, every hole adds detection solution A working solution 100 μ L (prepared before use), and ELISA Plate adds overlay film, and 37 DEG C of incubations 1 are little
Time.
4, discarding liquid in hole, every hole cleaning mixture of 350 μ L washs, and soaks 1～2 minute, sucks (untouchable plate
Wall) or get rid of the liquid in ELISA Plate, which floor absorbent paper of place mat in laboratory table, ELISA Plate is firmly clapped down several times (also can be light
Clap and liquid in hole patted dry), repeat to wash plate 3 times.After last washing, the cleaning mixture in hole be dried completely.Automatically wash
Trigger also may be used.
5, every hole adds detection solution B working solution (prepared before use) 100 μ L, adds overlay film, 37 DEG C of incubations 30 minutes.
6, discarding liquid in hole, dry, wash plate 5 times, method is with step 4.
7, every hole adds substrate solution 90 μ L, and ELISA Plate adds overlay film, and (response time controls 15～25 in 37 DEG C of lucifuge colour developings
Minute, do not exceed 30 minutes.When before gauge orifice, 3～4 holes have obvious gradient blue, when rear 3～4 gradient pores are inconspicuous,
Can terminate).
8, every hole adds stop bath 50 μ L, terminates reaction, and now blue standing turns yellow.The addition sequence of stop buffer should be tried one's best
Identical with the addition sequence of substrate solution.As uneven color one occurs, rock ELISA Plate the most gently so that solution mix homogeneously.
9, guaranteeing at the bottom of ELISA Plate in without water droplet and hole after bubble-free, immediately by microplate reader in each hole of 450nm wavelength measurement
Optical density (O.D. value).
(2)LPS
1, sample-adding: set gauge orifice, testing sample hole, blank well respectively.If gauge orifice 5 hole, it is sequentially added into 50 μ L differences dense
The standard substance (preparing 2 see reagent) of degree.Blank well adds 50 μ L (preparing last pipe of second step see reagent), and remaining hole adds testing sample
50 μ L, every hole adds detection solution A working solution 50 μ L immediately after, vibrates gently, and mixing has been careful not to bubble, and ELISA Plate adds
Upper overlay film, 37 DEG C of incubations 1 hour.
2, discarding liquid in hole, every hole cleaning mixture of 350 μ L washs, and soaks 1-2 minute, sucks (untouchable wooden partition)
Or get rid of the liquid in ELISA Plate, which floor absorbent paper of place mat in laboratory table, ELISA Plate firmly clap several times down (also can pat by
In hole, liquid pats dry), repeat to wash plate 3 times.After last washing, the cleaning mixture in hole be dried completely.Automatic washer
Also may be used.
3, every hole adds detection solution B working solution (prepared before use) 100 μ L, adds overlay film, 37 DEG C of incubations 30 minutes.
4, discarding liquid in hole, dry, wash plate 5 times, method is with step 2.
5, every hole adds substrate solution 90 μ L, and ELISA Plate adds overlay film, and (response time controls at 15-25 in 37 DEG C of lucifuge colour developings
Minute, do not exceed 30 minutes.After gauge orifice, 3 holes have obvious gradient blue, when front 3 gradient pores are inconspicuous,
Terminate).
6, every hole adds stop bath 50 μ L, terminates reaction, and now blue standing turns yellow.The addition sequence of stop buffer should be tried one's best
Identical with the addition sequence of substrate solution.As uneven color one occurs, rock ELISA Plate the most gently so that solution mix homogeneously.
7, guaranteeing at the bottom of ELISA Plate in without water droplet and hole after bubble-free, immediately by microplate reader in each hole of 450nm wavelength measurement
Optical density (O.D. value).
(3)TNF-α
1, sample-adding: set gauge orifice, testing sample hole, blank well respectively.If gauge orifice 7 hole, it is sequentially added into 100 μ L differences dense
The standard substance (preparing 2 see reagent) of degree.Blank well adds 100 μ L (preparing last pipe of second step see reagent), and remaining hole adds treats test sample
Product 100 μ L, ELISA Plate adds overlay film, 37 DEG C of incubations 2 hours.
2, discard liquid, dry, need not wash.
3, every hole adds detection solution A working solution 100 μ L (prepared before use), and ELISA Plate adds overlay film, and 37 DEG C of incubations 1 are little
Time.
4, discarding liquid in hole, every hole cleaning mixture of 350 μ L washs, and soaks 1-2 minute, sucks (untouchable wooden partition)
Or get rid of the liquid in ELISA Plate, which floor absorbent paper of place mat in laboratory table, ELISA Plate firmly clap several times down (also can pat by
In hole, liquid pats dry), repeat to wash plate 3 times.After last washing, the cleaning mixture in hole be dried completely.Automatic washer
Also may be used.
5, every hole adds detection solution B working solution (prepared before use) 100 μ L, adds overlay film, 37 DEG C of incubations 30 minutes.
6, discarding liquid in hole, dry, wash plate 5 times, method is with step 4.
7, every hole adds substrate solution 90 μ L, and ELISA Plate adds overlay film, and (response time controls 15～25 in 37 DEG C of lucifuge colour developings
Minute, do not exceed 30 minutes.When the front 3-4 hole of gauge orifice has obvious gradient blue, when rear 3-4 gradient pores is inconspicuous, i.e.
Can terminate).
8, every hole adds stop bath 50 μ L, terminates reaction, and now blue standing turns yellow.The addition sequence of stop buffer should be tried one's best
Identical with the addition sequence of substrate solution.As uneven color one occurs, rock ELISA Plate the most gently so that solution mix homogeneously.
9, guaranteeing at the bottom of ELISA Plate in without water droplet and hole after bubble-free, immediately by microplate reader in each hole of 450nm wavelength measurement
Optical density (O.D. value).
(4) NO detection
1、NaNO2The dilution of titer:
Take 7, test tube, successively label 1～7.Distilled water 1ml is added to 2～No. 7 test tubes successively, with dripping with burette 1
Fixed tube 2 adds NaNO to No. 1 test tube2Titer 2ml, then add No. 2 examinations with burette 2 from No. 1 test tube sucking-off 1ml liquid
Pipe, mixing, then sucking-off 1ml liquid add No. 3 test tubes, mixing.Repeat this step.Abandon when from No. 6 test tube sucking-off 1ml liquid
Go.Dilution step is shown in Fig. 4.
2,1% sulfanilamide 0.5ml is added to 1～No. 7 test tube successively with burette 3.
3,0.1%N-1-naphthyl ethylenediamine hydrochloric acid 0.5ml is added to 1～No. 7 test tube successively with burette 4.
4, mixing 1～7 tries liquid in pipe successively, hatches 20 minutes under room temperature.
5, with No. 7 examination liquid in pipe as a control group, the suction of 1～No. 6 examination liquid in pipe is measured respectively with spectrophotometer
Shading value record.
6, with burette dropping liquid time it should be noted that each burette is only used for each reagent, never use with.
6. prepared by model
Concrete operation method: rat weight labelling, abdominal part routine disinfection, 20% urethane 0.5mL/100g lumbar injection fiber crops
Liquor-saturated, extract previously prepared mixed bacteria liquid with 1mL syringe, left hand is held rat-tail and is mentioned rat, grinds off syringe needle with 10mL syringe
Point, the cervix uteri crotch bottom vagina carefully enters in the uterine cavity of side, syringe needle in uterine cavity back and forth pull 2 times with mechanicalness
Damage endometrial tissue, then injects bacterium solution 0.1mL towards ovary direction, and 0.1mL bacterium solution is injected another by same operating procedure
Aconitum carmichaeli Debx. palace, after injection, is inverted rat 5min, in case bacterium solution spills.Rat infection is respectively organized respectively at 24h, 48h observed and recorded
Situation, with rat without death, after modeling, difference vagina scraping blade after 24h, 72h, 96h, carries out bacterium colony cultivation, selects colony counting
The infection dosage of >=30 ,≤100 is as optimal infection dosage.Using this bacterium amount as the bacterium amount of In vivo infection.Tested rat infection
Bacterium amount is:
Table 1
All laboratory animals 24h, 72h and 96h after modeling, anesthesia, routine disinfection abdominal part, stretches into palace with aseptic cotton carrier
Mouthful, back and forth after pull 2 times, cotton swab is put in the test tube containing 2mL normal saline, it is thus achieved that containing test article suspension, takes out cotton swab,
Fully dipping mixed liquor uniform application in aseptic M-H (A) planar surface with new aseptic cotton carrier again, 35 DEG C of overnight incubation, after 18h
Carry out colony counting.240h sacrifices animal, observes uterine infection situation.Each group typical case Mus infects colony counting, result such as following table
2:
Table 2 tested rat infection bacterium amount
All laboratory animals 24h, 72h and 96h after modeling, anesthesia, routine disinfection abdominal part, show with without bacterium colony count results
Showing, 3 groups of Mus institute infection dosages meet requirement of experiment.Meanwhile, the visible inflammatory hyperemia directly perceived of uterus etc. seen from after dissection and inflammatory water
Swollen.
7. process of the test
(female SPF SD rat, 220g ± 20g, tested by Sichuan Academy of Medical Sciences for model and 150 rats of packet
Institute of Botany is buied, laboratory animal production licence number: SCXK (river) 2008-24).16 are served only for blank, raise separately.Its
Yu Jun injects mixed bacteria liquid after using modeling method anesthesia.Observe 5, the most daily randomly draw 6 only reach 2 anesthesia of blank group after
Gather vaginal secretions for nacterial smear.After 5 days, survival rats is randomly divided into 5 groups, i.e. model, AZM, AZMQR, AZMDG,
AZMFF (represents the model group of not treatment respectively, is used alone azithromycin group, azithromycin heat clearing away merging group, azithromycin
Lack Radix Angelicae Sinensis merging group, azithromycin the most just merging group).
Model: the not model group for the treatment of.
AZM: azithromycin treatment model group.
AZMQR: azithromycin+with Radix Flemingiae Philippinensis, Herba Andrographis, Radix Rosae Laevigatae, Caulis Mahoniae, Fructus Zanthoxyli Dissiti is according to FUKE QIANJIN PIAN formula
In ratio and method prepare compositions therapeutic alliance model group.
AZMDG: azithromycin+with Radix Flemingiae Philippinensis, Herba Andrographis, Radix Rosae Laevigatae, Caulis Mahoniae, Fructus Zanthoxyli Dissiti, Caulis Spatholobi, Radix Codonopsis is according to woman
Ratio and method in section's QIANJIN PIAN formula prepare compositions therapeutic alliance model group.
AZMFF: azithromycin+FUKE QIANJIN PIAN (include Radix Flemingiae Philippinensis, Herba Andrographis, Radix Rosae Laevigatae, Caulis Mahoniae, Fructus Zanthoxyli Dissiti, when
Return, Caulis Spatholobi, Radix Codonopsis composition, Zhuzhou Qianjin Pharmacy Co., Ltd produce) therapeutic alliance model group.
1. study dosage
(1) AZM dosage: the optional study dosage of azithromycin (AZM) is analyzed and determined by the present embodiment, purpose
For select one on probation after action intensity is moderate, duration is moderate study dosage, the most clearly with during Chinese medicine drug combination time
Cheng Changdu.Prerun 60,30,20,10mg/kg.d tri-days, find that former setting dosage is too high, finally use 10mg/kg.d.
(2) Test Drug Dosages:
According to result of study, the former dosage setting Chinese medicine composition is as 2.058g/kg.d, but prerun finds, this dosage is adopted
Prepare to volume by maximum is thin pulp shape to medicinal liquid, it is impossible to by gavage syringe needle.With adjusting final full side AZMFF dosage
For maximum dosage-feeding 1.66g/kg.d, adjust and lack when to be grouped into dosage AMZDG be 1.41g/kg.d, heat clearing away group dosage AMZQR is
1.16g/kg.d。
2. administration time
In addition to blank and model, after modeling the 6th day starts to give relative medicine.AZM gives respectively with each Chinese medicine, difference
About 2 hours time.All administration groups, at about 8 AZM the most first giving corresponding dosage, start after two hours to give accordingly
Chinese medicine normal saline water mixes thing.
3. sample collection
After 1st gives AZM two hours, respectively organize rat systemic vein blood through tail venous collection.From second day beginning each administration
Group rat twice blood sampling every day, before giving Archie and give before Chinese medicine each through tail venous collection the most once, gather blood volume about every time
0.3mL, sample time error about 30min.After administration gives AZM two hours on the 2nd, 4,6,8th, after each group anesthesia, sacrifice about 2
～4 rats, gather cavity of resorption tremulous pulse anticoagulated whole blood.
4. sample presentation test
All time point 0.3mL and last whole blood, take about 0.2mL blood plasma for last anticoagulated whole blood censorship hemocytometer
Number, lectin from hemolymph.Last blood plasma is used for detecting LPS, TNF-α, NO.
Shown in experimental result as Fig. 1 to Fig. 3.In accompanying drawing, be respectively indicated as from left to right AMZ, AMZDG, AZMFF,
The index variation situation of AZMQR, Model and normal group normal.
Result shows, after laboratory animal modeling, 3 kinds of inflammatory factor levels compare the most significantly raised with normal group, give not
After same combinational drug therapy, each coefficient all reduces, and trends towards replying normal level.Therapeutic effect ratio between each treatment group
Relatively, plasma endotoxin: AZMQR > AZMDG > AZM > AZMFF；Plasma Nitric Oxide: AZMQR AZMDG > AZMFF > AZM, blood plasma swells
Tumor necrosis factor: AZMFF > AZM > AZMDG > AZMQR.
Result above shows, shows that chronic pelvic inflammatory disease rat model plasma endotoxin, Plasma Nitric Oxide, Levels of tumor are bad
Necrosis factor, owing to infecting and the generation of inflammation, causes these three inflammatory factor to produce in a large number so that it is level is higher than normal value；Giving
After giving Drug therapy, inflammatory factor level all tends to recovering normal level, makees in intensity substantially between four kinds of medicines:
AZMQR>AZMDG>AZMFF>AZM。
Embodiment 2 applied research
1. object of study: select outpatient service voluntary in June, 2014 in February, 2015, because menoxenia, vagina irregularly go out
Blood, lower abdomen pendant pain or leucorrhoea grow in quantity, through being diagnosed as Patients with Pelvic Inflammatory Disease 30 example, age 35～52 years old.
The most all patients all routine examination routine blood test, liver and renal function before the treatment, take last blood plasma for detect LPS,
TNF-α、NO.The significantly raised patient of LPS, TNF-α, NO give Chinese medicine composition of the present invention (with Radix Flemingiae Philippinensis, Herba Andrographis, Radix Rosae Laevigatae,
Caulis Mahoniae and Fructus Zanthoxyli Dissiti prepare compositions, decoction or sheet with reference to formula proportion and the method for Zhuzhou a thousand pieces of gold Pharmaceutical FUKE QIANJIN PIAN
Agent) and azithromycin (with reference to azithromycin prescribed dose), azithromycin is separately taken with Chinese medicine composition of the present invention, during difference
Between about 2 hours.Take medicine continuously 2 weeks.Further consultation 1 time weekly during treatment, check routine blood test, LPS, TNF-α, NO index, liver and kidney
Function, understands untoward reaction and menstruation after medication.Without case lost to follow-up.
3. clinical symptoms: have vaginal hemorrhage person all after medication in 3～5 days blood only, lower abdomen pendant pain or leucorrhoea grow in quantity situation
Disappearing or alleviate, detection LPS, TNF-α, NO reply normal level.
Statistical result showed, in 30 examples, effective 10 examples, account for 33.3%；Effective 17 examples, 56.7%；Invalid 3 examples, account for 10%；
Total effective rate is 90%.
Claims (9)
1. the application in terms of preparation suppression inflammatory factor medicine of the heat clearing Chinese medicine compositions combined with antibiotic, described
Inflammatory factor includes plasma endotoxin, Plasma Nitric Oxide and/or plasma TNF；Described antibiotic is Archie
Mycin, the active component of described Chinese medicine composition is made up of Radix Flemingiae Philippinensis, Herba Andrographis, Radix Rosae Laevigatae, Caulis Mahoniae and Fructus Zanthoxyli Dissiti.
Application the most according to claim 1, it is characterised in that described application is that heat clearing Chinese medicine compositions is combined Zitromax
Element is applied to prepare targeted inhibition plasma endotoxin, Plasma Nitric Oxide and plasma TNF medicine aspect.
Application the most according to claim 1 and 2, it is characterised in that described application be by heat clearing Chinese medicine compositions associating Ah
Miramycin is applied to preparation treatment chronic pelvic inflammatory disease medicine aspect.
Application the most according to claim 1 and 2, it is characterised in that described application be by heat clearing Chinese medicine compositions associating Ah
Miramycin is applied to preparation treatment inflammation of uterus medicine aspect.
Application the most according to claim 1 and 2, it is characterised in that described application be by heat clearing Chinese medicine compositions associating Ah
Miramycin is applied to preparation treatment ovary inflammation medicine aspect.
Application the most according to claim 1 and 2, it is characterised in that in described Chinese medicine composition, Herba Andrographis and Fructus Zanthoxyli Dissiti
Incorporation is respectively the 9% of medical material gross weight；The incorporation of Radix Rosae Laevigatae, Caulis Mahoniae and Radix Flemingiae Philippinensis is respectively the 16% of medical material gross weight.
Mixing of application the most according to claim 3, it is characterised in that in described Chinese medicine composition, Herba Andrographis and Fructus Zanthoxyli Dissiti
Enter amount respectively for the 9% of medical material gross weight；The incorporation of Radix Rosae Laevigatae, Caulis Mahoniae and Radix Flemingiae Philippinensis is respectively the 16% of medical material gross weight.
Mixing of application the most according to claim 4, it is characterised in that in described Chinese medicine composition, Herba Andrographis and Fructus Zanthoxyli Dissiti
Enter amount respectively for the 9% of medical material gross weight；The incorporation of Radix Rosae Laevigatae, Caulis Mahoniae and Radix Flemingiae Philippinensis is respectively the 16% of medical material gross weight.
Mixing of application the most according to claim 5, it is characterised in that in described Chinese medicine composition, Herba Andrographis and Fructus Zanthoxyli Dissiti
Enter amount respectively for the 9% of medical material gross weight；The incorporation of Radix Rosae Laevigatae, Caulis Mahoniae and Radix Flemingiae Philippinensis is respectively the 16% of medical material gross weight.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610663187.2A CN106266149A (en) | 2016-08-12 | 2016-08-12 | The application in terms of preparation suppression inflammatory factor medicine of the heat clearing Chinese medicine compositions combined with antibiotic |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610663187.2A CN106266149A (en) | 2016-08-12 | 2016-08-12 | The application in terms of preparation suppression inflammatory factor medicine of the heat clearing Chinese medicine compositions combined with antibiotic |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106266149A true CN106266149A (en) | 2017-01-04 |
Family
ID=57670066
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610663187.2A Pending CN106266149A (en) | 2016-08-12 | 2016-08-12 | The application in terms of preparation suppression inflammatory factor medicine of the heat clearing Chinese medicine compositions combined with antibiotic |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106266149A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107884349A (en) * | 2017-10-13 | 2018-04-06 | 昆明理工大学 | The assay method of ultra-oxygen anion free radical in a kind of microbial body |
| CN113082187A (en) * | 2021-04-09 | 2021-07-09 | 北京红太阳药业有限公司 | Application of bupleurum tenue extract and azithromycin in combination in treatment of viral pneumonia |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1739656A (en) * | 2004-08-26 | 2006-03-01 | 江西仁和（集团）发展有限公司 | Prepn process of medicine for treating gynecopathy |
-
2016
- 2016-08-12 CN CN201610663187.2A patent/CN106266149A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1739656A (en) * | 2004-08-26 | 2006-03-01 | 江西仁和（集团）发展有限公司 | Prepn process of medicine for treating gynecopathy |
Non-Patent Citations (2)
| Title |
|---|
| 任守凤: "妇科千金胶囊治疗盆腔炎50例疗效分析", 《中国实用医药》 * |
| 李维等: "妇科千金片对阿奇霉素在慢性盆腔炎大鼠体内药物动力学的影响", 《中国中药杂志》 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107884349A (en) * | 2017-10-13 | 2018-04-06 | 昆明理工大学 | The assay method of ultra-oxygen anion free radical in a kind of microbial body |
| CN107884349B (en) * | 2017-10-13 | 2020-12-15 | 昆明理工大学 | Determination method of superoxide anion free radicals in microorganisms |
| CN113082187A (en) * | 2021-04-09 | 2021-07-09 | 北京红太阳药业有限公司 | Application of bupleurum tenue extract and azithromycin in combination in treatment of viral pneumonia |
| CN113082187B (en) * | 2021-04-09 | 2023-06-27 | 北京红太阳药业有限公司 | Application of bupleurum extract and azithromycin in combination for treating viral pneumonia |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100589807C (en) | Compound and its processing technology for compound sulfamonomethoxine sodium injection | |
| CN101869611A (en) | Admixture capable of repelling chicken coccidiosis and stopping dysentery and preparation method thereof | |
| CN100353953C (en) | Traditional Chinese medicina preparation for treating oral cavity, throat disease and its preparation method | |
| CN100512843C (en) | Chinese herbal composite prescription for controlling sea fish paralembus digitiformis | |
| CN106266149A (en) | The application in terms of preparation suppression inflammatory factor medicine of the heat clearing Chinese medicine compositions combined with antibiotic | |
| CN101700290B (en) | Pharmaceutical composition for preventing and treating warm-heat diseases of livestock and poultry and preparation method thereof | |
| CN108926584A (en) | The antimicrobial purposes of chimonanthea extract | |
| CN104888187B (en) | A kind of pharmaceutical composition for preventing and treating hybridized prussian carp gill hemorrhagic disease and preparation method thereof | |
| CN104127808A (en) | Traditional Chinese medicinal preparation for treating malignant tumors, and preparation method thereof | |
| CN117018018A (en) | Application of yeast-derived beta-glucan in preparation of medicines for preventing, treating or assisting in treating trichinosis | |
| CN103751755B (en) | It treats cow endometritis Chinese herbal medicine biological and closes first preparation and preparation method thereof | |
| CN104840424B (en) | A kind of hypericin albumin nanoparticle Escherichia coli serum antibody compound and its preparation method and application | |
| CN106389621A (en) | Application of combination of traditional Chinese medicinal composition and antibiotic in aspect of preparing medicines for inhibiting inflammatory factors | |
| CN106511347A (en) | Applications of nitidine chloride in preparing medicines for preventing/treating sepsis | |
| CN101411752A (en) | Granular formulation for treating children's pneumonia | |
| CN101380434A (en) | Yisheng granules and preparation method thereof | |
| CN104800276A (en) | Veterinary codonopsis pilosula atractylode and astragalus Chinese medicine preparation | |
| CN106138054A (en) | Chelerythrine application in treatment fowl drug resistance colibacillosis | |
| CN106138374A (en) | The application in terms of preparation treatment disease of thymus gland medicine of gynecological's prescriptions worth thousand gold compositions combined with antibiotic | |
| CN103417653B (en) | Veterinary-use compound pure Chinese herbal medicine for treating coccidium and preparation method of oral liquid of same | |
| CN105012201B (en) | The oral care product with anti-helicobacter pylori of the alcohol extract containing Chinese hawthorn seed | |
| CN109248219A (en) | A kind of application of Chinese medicine composition in the drug of preparation treatment brickpox | |
| CN103566276B (en) | A kind of Tibetan medicinal composition being used for the treatment of gastropathy and preparation method thereof | |
| CN108926583A (en) | The purposes of Zhejiang wintersweet anti-microbial infection | |
| CN105853481B (en) | The application of Hu Ci Aralia wood extract or the Chinese medicine composition containing Hu Ci Aralia wood extract |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170104 |